Evidence map›Paper›PMID 40897892›Full record

ArticleWorld journal of urology2025

Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registry.

Francesco Ditonno, Alessandro Veccia, Gabriele Bignante, Zhenjie Wu, Linhui Wang, Firas Abdollah, Alex Stephens, Giuseppe Simone, Gabriele Tuderti, Randall Lee and 39 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors.

Francesco DitonnoDepartment of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, 37126, Italy.
Alessandro VecciaDepartment of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, 37126, Italy.
Gabriele BignanteDepartment of Urology, Rush University, Chicago, IL, USA.
Zhenjie WuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Linhui WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Firas AbdollahHenry Ford Hospital, Vattikuti Urology Institute, Detroit, MI, USA.
Alex StephensHenry Ford Hospital, Vattikuti Urology Institute, Detroit, MI, USA.
Giuseppe SimoneDepartment of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gabriele TudertiDepartment of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Randall LeeDepartment of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Daniel D EunDepartment of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Andres F CorreaDepartment of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Ottavio De CobelliDivision of Urology, European Institute of Oncology IRCCS, Milan, Italy.
Matteo FerroDivision of Urology, European Institute of Oncology IRCCS, Milan, Italy.
Francesco PorpigliaDivision of Urology, University of Turin San Luigi Gonzaga Hospital, Turin, Italy.
Daniele AmparoreDivision of Urology, University of Turin San Luigi Gonzaga Hospital, Turin, Italy.
Enrico CheccucciDepartment of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Antonio TufanoDepartment of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Roberto ContieriDepartment of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Sisto PerdonàDepartment of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Raj BhanvadiaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Stephan BrönimannJohn Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, MD, USA.
Nirmish SinglaJohn Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, MD, USA.
James PorterSwedish Medical Center, Seattle, WA, USA.
Saum GhodoussipourSection of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Andrea MinerviniOncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, Florence, Italy.
Andrea MariOncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, Florence, Italy.
Luca LambertiniOncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, Florence, Italy.
Alireza GhoreifiDepartment of Urology, Duke University, Durham, NC, USA.
Omri Falik NativUniversity of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, FL, USA.
Mark L GonzalgoUniversity of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, FL, USA.
Daniel SidhomDepartment of Urology, Indiana University, Indianapolis, IN, USA.
Chandru P SundaramDepartment of Urology, Indiana University, Indianapolis, IN, USA.
Reuben Ben-DavidDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Ahmed ErakyDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Reza MehrazinDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Takashi YoshidaKansai Medical University, Osaka, Japan.
Hidefumi KinoshitaKansai Medical University, Osaka, Japan.
Alireza DehghanmanshadiDepartment of Urology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Soroush Rais-BahramiDepartment of Urology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Margaret F MeagherDepartment of Urology, UC San Diego School of Medicine, La Jolla, San Diego, CA, USA.
Dhruv PuriDepartment of Urology, UC San Diego School of Medicine, La Jolla, San Diego, CA, USA.
Ithaar H DerweeshDepartment of Urology, UC San Diego School of Medicine, La Jolla, San Diego, CA, USA.
Farshad S MoghaddamNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Hooman DjaladatNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Riccardo BertoloDepartment of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, 37126, Italy.
Riccardo AutorinoDepartment of Urology, Rush University, Chicago, IL, USA.
Alessandro AntonelliDepartment of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, 37126, Italy. alessandro_antonelli@me.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) in solitary kidney patients is a rare and underreported scenario. This study aims to compare the outcomes of UTUC solitary kidney patients becoming anephric after RNU to those of patients undergoing kidney-sparing surgery (KSS).

methodsData from patients with a solitary kidney were retrieved from the ROBUUST 2.0 database, a global, multicenter registry containing data on patients who underwent curative surgery for UTUC. Baseline patient demographics, disease characteristics, and surgical features were compared between RNU and KSS. Kaplan-Meier methods were used to estimate recurrence-free survival (RFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) in patients undergoing RNU, with 3-year and 5-year cutoffs applied.

resultsThirty-nine patients (76.5%) underwent RNU, whereas 12 (23.5%) underwent KSS. Despite a comparable preoperative renal function, the distribution of CKD stages differed significantly between the groups (p = 0.019). Despite a similar rate of postoperative complications, patients undergoing RNU experienced a significantly higher median LOS (p < 0.001). Among RNU patients, OS was 83.9%, CSS was 96.9%, RFS was 71.8%, and MFS was 84.4% at the 3-year follow-up. After 5 years post-surgery, OS was 73.4%, CSS was 83.1%, RFS was 59.9%, and MFS was 78.5% in the same cohort.

conclusionsUTUC solitary kidney patients undergoing RNU or KSS face a substantial perioperative burden. Despite these challenges, our cohort demonstrated favorable oncological outcomes comparable to those reported in the existing literature.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsNephrectomyNephroureterectomyOrgan Sparing TreatmentsSolitary KidneyUreteral NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesSurvival RatePostoperative complicationsRadical nephroureterectomyRenal insufficiencySolitary kidneyUpper tract urothelial carcinoma

Identifiers

PMID40897892
PMCPMC12405301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.